Relevant bibliographies by topics / P-PBPK model

Contents

  1. Journal articles
  2. Dissertations / Theses

Academic literature on the topic 'P-PBPK model'

Author: Grafiati
Published: 22 June 2024
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'P-PBPK model.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "P-PBPK model"

1

Mi, Kun, Shanju Pu, Yixuan Hou, et al. "Optimization and Validation of Dosage Regimen for Ceftiofur against Pasteurella multocida in Swine by Physiological Based Pharmacokinetic–Pharmacodynamic Model." International Journal of Molecular Sciences 23, no. 7 (2022): 3722. http://dx.doi.org/10.3390/ijms23073722.

Full text
Abstract:
Model informed drug development is a valuable tool for drug development and clinical application due to its ability to integrate variability and uncertainty of data. This study aimed to determine an optimal dosage of ceftiofur against P. multocida by ex vivo pharmacokinetic/pharmacodynamic (PK/PD) model and validate the dosage regimens by Physiological based Pharmacokinetic-Pharmacodynamic (PBPK/PD) model. The pharmacokinetic profiles of ceftiofur both in plasma and bronchoalveolar lavage fluid (BALF) are determined. PD performance of ceftiofur against P. multocida was investigated. By establi
APA, Harvard, Vancouver, ISO, and other styles
2

Jeong, Yoo-Seong, Min-Soo Kim, Nora Lee, et al. "Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans." Pharmaceutics 13, no. 6 (2021): 813. http://dx.doi.org/10.3390/pharmaceutics13060813.

Full text
Abstract:
Fexuprazan is a new drug candidate in the potassium-competitive acid blocker (P-CAB) family. As proton pump inhibitors (PPIs), P-CABs inhibit gastric acid secretion and can be used to treat gastric acid-related disorders such as gastroesophageal reflux disease (GERD). Physiologically based pharmacokinetic (PBPK) models predict drug interactions as pharmacokinetic profiles in biological matrices can be mechanistically simulated. Here, we propose an optimized and validated PBPK model for fexuprazan by integrating in vitro, in vivo, and in silico data. The extent of fexuprazan tissue distribution
APA, Harvard, Vancouver, ISO, and other styles
3

Dallmann, A., P. Mian, P. Annaert, M. Pfister, K. Allegaert, and J. van den Anker. "P21 PBPK modeling in pregnancy: achievements, shortcomings and future perspectives." Archives of Disease in Childhood 104, no. 6 (2019): e25.2-e25. http://dx.doi.org/10.1136/archdischild-2019-esdppp.59.

Full text
Abstract:
BackgroundPhysiologically-based pharmacokinetic (PBPK) models are considered a promising approach to better characterize and anticipate the effect of physiological changes on pharmacokinetics in pregnant women. Consequently, multiple pregnancy PBPK models have been developed and verified over the past years. Using acetaminophen (paracetamol) as example, PBPK modeling can provide specific insights into the expected pharmacokinetic changes throughout pregnancy.MethodsTo obtain an overview of pregnancy PBPK models, the scientific literature was systematically screened for publications with a focu
APA, Harvard, Vancouver, ISO, and other styles
4

Nauwelaerts, Nina, Julia Macente, Neel Deferm, et al. "Generic Workflow to Predict Medicine Concentrations in Human Milk Using Physiologically-Based Pharmacokinetic (PBPK) Modelling—A Contribution from the ConcePTION Project." Pharmaceutics 15, no. 5 (2023): 1469. http://dx.doi.org/10.3390/pharmaceutics15051469.

Full text
Abstract:
Women commonly take medication during lactation. Currently, there is little information about the exposure-related safety of maternal medicines for breastfed infants. The aim was to explore the performance of a generic physiologically-based pharmacokinetic (PBPK) model to predict concentrations in human milk for ten physiochemically diverse medicines. First, PBPK models were developed for “non-lactating” adult individuals in PK-Sim/MoBi v9.1 (Open Systems Pharmacology). The PBPK models predicted the area-under-the-curve (AUC) and maximum concentrations (Cmax) in plasma within a two-fold error.
APA, Harvard, Vancouver, ISO, and other styles
5

R.P., Sharma, Schuhmacher M., and Kumar V. "The development of a pregnancy PBPK Model for Bisphenol A and its evaluation with the available biomonitoring data." Science of the Total Environment 624 (May 15, 2018): 55–68. https://doi.org/10.1016/j.scitotenv.2017.12.023.

Full text
Abstract:
Recent studies suggest universal fetal exposure to Bisphenol A (BPA) and its association with the adverse birth outcomes. Estimation of the fetal plasma BPA concentration from the maternal plasma BPA would be highly useful to predict its associated risk to this specific population. The objective of current work is to develop a pregnancy-physiologically based pharmacokinetic (P-PBPK) model to predict the toxicokinetic profile of BPA in the fetus during gestational growth, and to evaluate the developed model using biomonitoring data obtained from different pregnancy cohort studies. To achieve th
APA, Harvard, Vancouver, ISO, and other styles
6

Yang, Zhuan, Yuchen Qu, Yewen Sun, Jie Pan, Tong Zhou, and Yunli Yu. "Evaluation of Drug–Drug Interactions Between Clarithromycin and Direct Oral Anticoagulants Using Physiologically Based Pharmacokinetic Models." Pharmaceutics 16, no. 11 (2024): 1449. http://dx.doi.org/10.3390/pharmaceutics16111449.

Full text
Abstract:
Objective: This study assessed the pharmacokinetic (PK) interactions between clarithromycin (a P-glycoprotein [P-gp] inhibitor) and four direct oral anticoagulants (DOACs) (P-gp substrates) using physiologically based PK (PBPK) models to elucidate the influence of P-gp in the interaction between them. Methods: PBPK models for clarithromycin, DABE–dabigatran (DAB), rivaroxaban, apixaban, and edoxaban were constructed using GastroPlus™ (version 9.9), based on physicochemical data and PK parameters from the literature. The models were optimized and validated in healthy subjects. We evaluated the
APA, Harvard, Vancouver, ISO, and other styles
7

Costa, Bárbara, Maria João Gouveia, and Nuno Vale. "PBPK Modeling of Lamotrigine and Efavirenz during Pregnancy: Implications for Personalized Dosing and Drug-Drug Interaction Management." Pharmaceutics 16, no. 9 (2024): 1163. http://dx.doi.org/10.3390/pharmaceutics16091163.

Full text
Abstract:
This study aimed to model the pharmacokinetics of lamotrigine (LTG) and efavirenz (EFV) in pregnant women using physiologically based pharmacokinetic (PBPK) and pregnancy-specific PBPK (p-PBPK) models. For lamotrigine, the adult PBPK model demonstrated accurate predictions for pharmacokinetic parameters. Predictions for the area under the curve (AUC) and peak plasma concentration (Cmax) generally agreed well with observed values. During pregnancy, the PBPK model accurately predicted AUC and Cmax with a prediction error (%PE) of less than 25%. The evaluation of the EFV PBPK model revealed mixed
APA, Harvard, Vancouver, ISO, and other styles
8

Ali-Daoud, Yourdasmine, Cleo Tebby, Rémy Beaudouin, and Céline Brochot. "Development of a physiologically based toxicokinetic model for lead in pregnant women: the role of bone tissue in the maternal and fetal internal exposure." Toxicology and Applied Pharmacology 476 (August 29, 2023): 116651. https://doi.org/10.5281/zenodo.8297909.

Full text
Abstract:
Epidemiological studies have shown associations between prenatal exposure to lead (Pb) and neurodevelopmental effects in young children. Prenatal exposure is generally characterized by measuring the concentration in the umbilical cord at delivery or in the maternal blood during pregnancy. To assess internal Pb exposure during prenatal life, we developed a pregnancy physiologically based pharmacokinetic (p-PBPK) model that to simulates Pb levels in blood and target tissues in the fetus, especially during critical periods for brain development. An existing Pb PBPK model was adapted to pregnant w
APA, Harvard, Vancouver, ISO, and other styles
9

Kovar, Lukas, Christina Schräpel, Dominik Selzer, et al. "Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates." Pharmaceutics 12, no. 6 (2020): 578. http://dx.doi.org/10.3390/pharmaceutics12060578.

Full text
Abstract:
Buprenorphine plays a crucial role in the therapeutic management of pain in adults, adolescents and pediatric subpopulations. However, only few pharmacokinetic studies of buprenorphine in children, particularly neonates, are available as conducting clinical trials in this population is especially challenging. Physiologically-based pharmacokinetic (PBPK) modeling allows the prediction of drug exposure in pediatrics based on age-related physiological differences. The aim of this study was to predict the pharmacokinetics of buprenorphine in pediatrics with PBPK modeling. Moreover, the drug-drug i
APA, Harvard, Vancouver, ISO, and other styles
10

Pilla Reddy, Venkatesh, Adrian J. Fretland, Diansong Zhou, et al. "Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors." Cancer Chemotherapy and Pharmacology 88, no. 3 (2021): 451–64. http://dx.doi.org/10.1007/s00280-021-04302-5.

Full text
Abstract:
Abstract Purpose Limited information is available regarding the drug–drug interaction (DDI) potential of molecular targeted agents and rituximab plus cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone (R-CHOP) therapy. The addition of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib to R-CHOP therapy results in increased toxicity versus R-CHOP alone, including higher incidence of peripheral neuropathy. Vincristine is a substrate of P-glycoprotein (P-gp, ABCB1); drugs that inhibit P-gp could potentially cause increased toxicity when co-administered wi
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "P-PBPK model"

1

Ali, daoud Yourdasmine. "Une Approche quantitative de l'exposition fœtale au plomb : développement d'un modèle pharmacocinétique basé sur la physiologie de la grossesse (p-PBPK) et application aux données de biosurveillance." Electronic Thesis or Diss., Paris, AgroParisTech, 2024. http://www.theses.fr/2024AGPT0001.

Full text
Abstract:
Le plomb (Pb) est une neurotoxine très puissante, notamment pour les enfants. Une vaste littérature épidémiologique documente les effets de l'exposition au Pb chez les jeunes enfants. Le Pb est capable de traverser la barrière placentaire pour induire une exposition précoce du fœtus. Cette exposition prénatale est associée à une altération des fonctions cognitives des enfants qui se traduit par des problèmes d'apprentissage, une diminution du quotient intellectuel (QI) et des problèmes de comportement. Pour des raisons d'éthique évidentes, il n'est pas possible de mesurer la concentration de P
APA, Harvard, Vancouver, ISO, and other styles
2

Chow, Edwin C. Y. "Biological Roles of the Vitamin D Receptor in the Regulation of Transporters and Enzymes on Drug Disposition, Including Cytochrome P450 (CYP7A1) on Cholesterol Metabolism." Thesis, 2012. http://hdl.handle.net/1807/36277.

Full text
Abstract:
Nuclear receptors play significant roles in the regulation of transporters and enzymes to balance the level of endogenous molecules and to protect the body from foreign molecules. The vitamin D receptor (VDR) and its natural ligand, 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3], was shown to upregulate rat ileal apical sodium dependent bile acid transporter (Asbt) to increase the reclamation of bile acids, ligands of the farnesoid X receptor (FXR). FXR is considered to be an important, negative regulator of the cholesterol metabolizing enzyme, Cyp7a1, which metabolizes cholesterol to bile acids
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'P-PBPK model' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography